Hengrui makes headway with novel drugs but investors bide their time
A cancer drug developed by the Chinese firm has entered the European regulatory process and Novo Nordisk has bought rights to a potential weight-loss therapy Key Takeaways: Hengrui Pharma’s cancer…
Drug setback leaves Ascletis with an all-in bet on weight loss
The company’s two core hepatitis drugs were dropped from China’s state insurance scheme on July 1, effectively wiping out the remains of its legacy drug sales Key Takeaways: The company…
WuXi AppTec wages buyback campaign as U.S. pressure mounts
The drug services provider has been battling to shore up its share price and suffered a sharp sell-off after being added to a U.S. list of firms with suspected military…
Then there were two: BeOne moves beyond single-blockbuster dependence
The company’s Sonrotoclax is the first newly approved BCL-2 inhibitor in the U.S. in nearly a decade, giving BeOne a potential new hit beyond its Zanubrutinib blood cancer therapy Key…
Big deal, bigger doubts: CSPC slides after $18.5 billion pact
After months of rumors drove up its share price, the Chinese drug company has unveiled a record licensing deal with AstraZeneca, only to see its stock tumble Key Takeaways: Going…
Lagging in the weight-loss market? Take Fosun’s GLP-1 pill
Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal Key Takeaways: With the drug still…
3SBio gears up for drugs battle with $400 million equity move
After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary Key takeaways: 3SBio…
Recent Articles
Hengrui makes headway with novel drugs but investors bide their time
1276.HK
600276.SHG
WuXi AppTec wages buyback campaign as U.S. pressure mounts
2359.HK
603259.SHG
Then there were two: BeOne moves beyond single-blockbuster dependence
6160.HK
688235.SHG
ONC.US
Lagging in the weight-loss market? Take Fosun’s GLP-1 pill
2196.HK
600196.SHG
RELATED ARTICLES
-
Drug spin-off trend gains traction with IPO by Hengrui offshoot
1276.HK600276.SHG - Hansoh’s overseas ambitions tested as EU stalls cancer drug sales
-
Can a novel sleeping pill help Jingxin shed its generic label?
002020.SHE
-
Cancer drug sales power up Kelun-Biotech’s profit engine
6990.HK
-
Salubris refiles for Hong Kong IPO as generics lose steam
002294.SHE
-
Drug setback leaves Ascletis with an all-in bet on weight loss
1672.HK
-
Then there were two: BeOne moves beyond single-blockbuster dependence
6160.HK688235.SHGONC.US
